Roche's Gazyvaro, a drug that can restore kidney function in people living with lupus nephritis, has been cleared for use by ...

How would you treat a 30-year-old woman with systemic lupus erythematous (SLE) and lupus nephritis (LN) class 3 with new ...

Investigators studied expression of type I interferons, key pathogenic drivers in systemic lupus erythematosus and lupus nephritis.

The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Low proteinuria does not indicate better kidney outcomes or treatment response in patients with lupus nephritis; glomerulosclerosis predicts renal function decline, especially in relapsing disease.

This transcript has been edited for clarity. Matthew A. Sparks, MD: I'm Dr Matthew Sparks, and welcome to Medscape's InDiscussion podcast series on chronic kidney disease. Today we'll be discussing ...

The lupus nephritis category is sporting a first-ever brand battle—two new-to-category drugs with very different profiles and marketing strategies. GlaxoSmithKline’s Benlysta, the tried-and-true drug ...

When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and glucocorticoids.

Patients who received obinutuzumab were less likely to experience a renal-related event or death, compared with those who received placebo. The Food and Drug Administration (FDA) has approved Gazyva ® ...